Condition (MeSH)
Aortic Valve Stenosis
ClinicalTrials.gov lists 1,368 trials for Aortic Valve Stenosis or a narrower condition beneath it. Edwards Lifesciences has the most among industry and government lead sponsors, with 41.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
985 of the 1,368 trials are tagged with Aortic Valve Stenosis itself; the rest are tagged with a narrower condition beneath it.
When did Aortic Valve Stenosis trials start? (35)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 110
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 85 |
| 2025 | 105 |
| 2024 | 110 |
| 2023 | 107 |
| 2022 | 73 |
| 2021 | 70 |
| 2020 | 89 |
| 2019 | 82 |
| 2018 | 78 |
| 2017 | 77 |
Showing 10 of 35 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 100 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 131 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 672 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Aortic Valve Stenosis trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 26 |
| Phase 1/2 | 3 |
| Phase 2 | 57 |
| Phase 2/3 | 13 |
| Phase 3 | 50 |
| Phase 4 | 69 |
| Not applicable | 521 |
| Observational | 628 |
| Expanded access | 1 |
How many Aortic Valve Stenosis trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 81 |
| Recruiting | 247 |
| Enrolling by invitation | 29 |
| Active, not recruiting | 100 |
| Completed | 549 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Aortic Valve Stenosis trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Edwards Lifesciences | 41 |
| National Heart, Lung, and Blood Institute (NHLBI) | 36 |
| Bristol-Myers Squibb | 25 |
| Abbott Medical Devices | 24 |
| Medtronic Cardiovascular | 17 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Aortic Valve Stenosis? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Aficamten | 8 |
| Levosimendan | 5 |
| .spironolactone | 4 |
| Rivaroxaban | 4 |
| Perhexiline | 4 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Mavacamten Capsule 2 | 37 |
| EC Aspirin | 8 |
| Metoprolol XL | 5 |
| HRS-1893 | 4 |
| Low dose losartan | 4 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Aortic Valve Stenosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Other | 1,768 | 15 |
| Total | 1,246 | 1 |
| Atrioventricular block complete | 1,009 | 20 |
| Cardiac Conduction Disorders | 943 | 5 |
| Anaemias | 755 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Aortic Valve Stenosis? (1,595)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effect of cerebral embolic protection device on new cerebral embolism during transcatheter aortic valve replacement: A prospective sentinel registry. | American heart journal | 2026 | Yes |
| Innovations in Aortic Valve Replacement: A Comprehensive Overview of the Intuity Rapid Deployment Valve. | Cardiology in review | 2026 | Yes |
| The low-risk TAVR trials-A critical appraisal of the current landscape. | American heart journal | 2026 | Yes |
| Self-expanding versus balloon-expandable transcatheter heart valves in patients with excessive aortic valve cusp calcification. | American heart journal | 2026 | Yes |
| Routine versus selective protamine administration to reduce bleeding after TAVI: Rationale and design of the POPular ACE TAVI trial. | American heart journal | 2026 | Yes |
Showing 5 of 1,595 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.